RXi Pharmaceuticals and Gustave Roussy Announce Research Collaboration

MARLBOROUGH, Mass., Nov. 13, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a clinical-stage company developing a new class of RNAi-based therapeutics, and Gustave Roussy, a leading Comprehensive Cancer Centre in Europe, today announced that they have entered into a collaborative research agreement to evaluate the potential of RXi's novel sd-rxRNA technology platform for use in cancer treatments.  The agreement covers research to design and evaluate sd-rxRNA compounds in a human tumor xenograft model.  Positive results may lead to further development of these compounds for treatment of cancer.

Logo - http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg

"We are excited to be working with Gustave Roussy on this research effort," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals.  He further added, "We believe that our sd-rxRNA technology platform is broadly applicable to many therapeutic areas, including cancer.  Considering our sd-rxRNA development for immuno-oncology applications, we look forward to working with the exceptional team at this prominent cancer center to leverage their expertise in this area."

Professor Caroline Robert, MD, PhD, head of the Dermatology Unit at the Gustave Roussy Institute which focuses on skin cancer research, said that "the innovative technology developed by RXi will allow us to address several critical questions in the field of cancer research and to explore future potential use of siRNAs in the clinic."

About Gustave Roussy

Gustave Roussy, the largest comprehensive cancer center in Europe, is a pole of expertise dedicated to the comprehensive care of patients, employing 3,100 health professionals for health care, research and teaching. – www.gustaveroussy.fr/en

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs.  Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which can be used to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition.  RXi developed a robust RNAi therapeutic platform, including self-delivering RNA (sd-rxRNA®) compounds, that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. Our current programs include dermatology, ophthalmology, and cell-based immunotherapy.  RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas, and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies.  For additional information, visit the Company's website, www.rxipharma.com. 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors."  Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646

SOURCE RXi Pharmaceuticals Corporation

Related Links

http://www.rxipharma.com